Maze Therapeutics (MAZE) Long-Term Debt Issuances (2026)

Maze Therapeutics' (MAZE) quarterly Long-Term Debt Issuances came in at $39.4 million in Q1 2026.

Maze Therapeutics (MAZE) Long-Term Debt Issuances (2026) Analysis & Trends

Maze Therapeutics has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $39.4 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 2.73 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Maze Therapeutics 1.31 Bn 1.31 Bn 18.21 Mn 39.40 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 39.40 Mn
Mar 31, 2026 39.40 Mn